Cellceutix Retains Ashcroft Law Firm, Seeks Withdrawal of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cellceutix Retains Ashcroft Law Firm, Seeks Withdrawal of Complaint

BOSTON, MA --(Marketwired - October 02, 2015) - Cellceutix Corporation ( OTC : CTIX ), issues the following statement in connection with the recent filing of a frivolous and baseless lawsuit in New York:

Cellceutix, headquartered in Beverly, Massachusetts, has retained the Ashcroft Law Firm -- led by Michael J. Sullivan, former United States Attorney for the District of Massachusetts -- to investigate, address and defend frivolous claims filed by the Rosen Law Firm in the U.S. District Court for the Southern District of New York (Case 1:15-cv-07194-KPF).

Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antimicrobial applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships.

In the event Cellceutix is formally served with the complaint, it will deny the allegations in the lawsuit and will vigorously defend itself and its shareholders from this contemptible action. The allegations -- apparently gleaned from an article of highly dubious origin -- are fictional, and, in the company's view, represents a cynical attempt to improperly manipulate the value of its stock offerings and/or unfairly attack a rapidly emerging company.

Cellceutix is proud of its performance and successes within the industry and is deeply disappointed by the baseless claims of the Rosen Law Firm and the plaintiffs in this action.

"Mako Research (the apparent author of a Seeking Alpha article), the Rosen Law Firm and the plaintiffs, have launched a wholly unjustified attack on Cellceutix and its managing members," said Michael J. Sullivan of the Ashcroft Law Firm. "Based on our initial review, this litigation is entirely without merit and it is apparent that the Rosen Law Firm's complaint relied almost exclusively on a scandalous and meritless article published on Seeking Alpha, and should be immediately, voluntarily withdrawn in order to mitigate future harm to this Company."

Should it become necessary, Cellceutix plans to argue that Rosen Law Firm filed its improper complaint without first investigating the factual basis of the allegations as required by the law and professional standards. Absent a withdrawal of this Complaint, Cellceutix intends to seek both a dismissal of this action and sanctions against Rosen Law Firm for initiating this frivolous lawsuit and for failing to conduct any reasonable due diligence which would have shown that the allegations are false.

Currently, Cellceutix's anti-cancer drug Kevetrin is in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. In the Phase 1 trial, p53 activity is evidenced through increased expression of p21, a downstream biomarker of p53.

Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol is in a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction.

Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs).

Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, Fox Chase Chemical Diversity Center, and the University of Bologna.

About The Ashcroft Law Firm: The Ashcroft Law Firm was founded by former U.S. Attorney General, Governor and Senator John Ashcroft, and has offices in Boston, MA, Washington, DC, St. Louis, MO, and Austin, TX. See http://ashcroftlawfirm.com/ for more information.

Alerts: Sign-up for Cellceutix email alerts is available at http://cellceutix.com/email-alerts/ - sthash.CRfqSmmY.dpbs

Cellceutix clinical trials on Clinicaltrials.gov: https://clinicaltrials.gov/ct2/results?term=c...rch=Search

About Cellceutix:

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". More information is available on the Cellceutix web site at www.cellceutix.com .

Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Cellceutix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. Cellceutix has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Cellceutix's need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that Cellceutix's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in Cellceutix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Cellceutix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

INVESTOR AND MEDIA CONTACT: Cellceutix Corporation Leo Ehrlich Email contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 60

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading

Top 5 Most Recently Viewed Articles

American Atomics Welcomes New Director and Operational Experts

Updated Category News Views 236

American Atomics Welcomes a New Addition to Its Leadership Team American Atomics Inc. (the "Company") is excited to announce the addition of Mr. Henrik Mikkelsen to its Board of Directors. With over 30 years of expertise in investment banking and energy trading, Mr. Mikkelsen will significantly bolster the company's direction. His recent role as Managing Partner and CIO...

Continue Reading
Coinbase Price Target Surges: Insights from Top Analysts

Updated Category News Views 127

Analyst Predictions for Coinbase's Future In the dynamic landscape of finance, the role of expert analysts becomes paramount, especially when it comes to predicting movements in stock prices. A recent surge in forecasts suggests that Coinbase Global, Inc. (NASDAQ: COIN) could experience substantial growth in its stock value. With the price target moving from $280 to an...

Continue Reading
Insights on Ultra Clean Holdings' Upcoming Class Action Lawsuit

Updated Category News Views 192

Understanding the Class Action Lawsuit Against Ultra Clean Holdings The Gross Law Firm is here to inform investors of Ultra Clean Holdings, Inc. (NASDAQ: UCTT) about an important class action lawsuit that is currently pending. This notice is directed towards shareholders who acquired shares of UCTT during the specified class period. The opportunity to participate in this...

Continue Reading
Logistics Automation Market Expected to Hit $85.19 Billion

Updated Category News Views 78

Growth of the Logistics Automation Market The logistics automation market is experiencing a transformative shift, with projections indicating that it will reach an impressive US$ 85.19 billion by 2030. This signifies a substantial increase from the US$ 35.21 billion recorded in 2022, with a compound annual growth rate (CAGR) of 11.7% expected over the period spanning 2022...

Continue Reading
Exploring Wynn Resorts' Recent Options Activity and Insights

Updated Category News Views 115

Understanding the Latest Trends in Wynn Resorts' Options Wynn Resorts has been capturing the attention of investors lately, particularly those who are willing to take a more aggressive approach in the marketplace. The underlying sentiment indicates strong, bullish activity surrounding Wynn Resorts (NASDAQ: WYNN). This is particularly significant for both institutional and...

Continue Reading